Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Payables (2016 - 2025)

Historic Payables for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to $32.9 million.

  • Arrowhead Pharmaceuticals' Payables rose 12782.74% to $32.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $32.9 million, marking a year-over-year increase of 12782.74%. This contributed to the annual value of $17.7 million for FY2025, which is 5519.85% up from last year.
  • Arrowhead Pharmaceuticals' Payables amounted to $32.9 million in Q4 2025, which was up 12782.74% from $17.7 million recorded in Q3 2025.
  • Arrowhead Pharmaceuticals' 5-year Payables high stood at $35.9 million for Q3 2023, and its period low was $796000.0 during Q4 2022.
  • For the 5-year period, Arrowhead Pharmaceuticals' Payables averaged around $13.1 million, with its median value being $9.8 million (2023).
  • Per our database at Business Quant, Arrowhead Pharmaceuticals' Payables tumbled by 8043.26% in 2022 and then soared by 115055.79% in 2023.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Payables (Quarter) stood at $4.1 million in 2021, then tumbled by 80.43% to $796000.0 in 2022, then skyrocketed by 460.3% to $4.5 million in 2023, then skyrocketed by 224.15% to $14.5 million in 2024, then surged by 127.83% to $32.9 million in 2025.
  • Its last three reported values are $32.9 million in Q4 2025, $17.7 million for Q3 2025, and $33.0 million during Q2 2025.